UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other Cancer Subpopulation

Core Viewpoint - UroGen Pharma (NASDAQ: URGN) is rated as a "hold" ahead of its upcoming Prescription Drug User Fee Act (PDUFA) review for UGN-102 (mitomycin) [2] Company Analysis - The FDA has set a date to review the regulatory application of UGN-102, which is an intravesical treatment [2] - The article is part of a broader service that provides in-depth analysis of various pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2]